Vonoprazan not linked to risk for Clostridioides difficile

2021-06-09

The use of vonoprazan to relieve acid reflux does not increase the risk for Clostridioides difficile, according to a study in the American Journal of Gastroenterology. The retrospective study examined more than 4,400 patients with Clostridioides difficile in a Japanese hospital database and more than 13,000 without the infection.

Full story:

ACG SmartBrief

Providing the latest, need-to-know medical headlines and news that affect gastroenterologists

Designed specifically for digestive disorder specialists, ACG SmartBrief is a FREE, twice-weekly e-mail newsletter. By providing the latest, need-to-know medical headlines and news that affect gastroenterologists, ACG SmartBrief saves you time and keeps you smart.